Dr Sethupathi Muthuramalingam
Last updated: 03/12/2024
Overview
125
|
total admissions. |
This information has been verified as accurate by the consultant
Last updated: 03/12/2024
125
|
total admissions. |
This information has been verified as accurate by the consultant
This information is provided by Dr Sethupathi Muthuramalingam.
GMC reg: 5176876I graduated from India and obtained an MD in General Medicine from one of the prestigious central institutes (JIPMER) in India. I was awarded a Gold medal by the University for the most outstanding performance in the MD examination. My general oncology training started in the Republic of Ireland and then I spent fours years in the Oxford Medical Oncology training programme, leading to the completion of specialist training in oncology. I took part in various research activities during my training and I was awarded the American Society of Oncology Merit Award for the quality research paper abstract submitted in one of their meetings. In 2005 I was appointed as a Consultant Medical Oncologist at Portsmouth Hospitals NHS Trust. As an oncologist with a special interest in colorectal, lung cancer and mesothelioma, my expertise is treating cancer patients with chemotherapy, biological therapies, targeted therapies and also immunotherapies. I also use molecular tests like next generation sequencing (NGS) and genetic tests to guide treatment decisions and reduce the toxicities from treatment. In addition, I take part in many clinical trials and I was and am the principal investigator of a few of the trials. I have extensive knowledge in managing symptoms associated with cancer and I work very closely with the palliative care and pain team.
Medical oncology
Tamil
Chemotherapy for colorectal, lung cancer and mesothelioma. Use of the biological therapies in the treatment of cancer like bevacizumab, cetuximab and Panitumumab. Use of the targeted therapies in the treatment of cancer like osimertinib, alectinib, sotorasib, etc. Use of the immunotherapies in the treatment of cancer like Pembrolizumab and nivoulumab. Application of Molecular tests including next generation sequencing (NGS) which help to guide targeted treatments. Application of Genetic tests like DPD and MSI, which might influence treatment decision making in colorectal cancer patients. Application of liquid biopsy (circulating tumour DNA) to guide and monitor cancer treatments. Leading and participating in clinical trials in the Portsmouth Hospitals NHS trust.
Surveys from patients about the care they received from Dr Sethupathi Muthuramalingam.
…
|
Not enough data available to show patient satisfaction feedback. |
…
|
Not enough data available to show patient experience feedback. |
Prices provided by Dr Sethupathi Muthuramalingam and their associated hospitals.
Spire Portsmouth Hospital
Queen Alexandra Hospital
Use our interactive chart to explore more fees information in your area .